SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced that SYS6010, its epidermal growth factor receptor...
SHE: 300765
CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced today the initiation and public registration of...